ONCOLOGY

Diagnostic performance of imaging for the detection of peritoneal metastases: a meta-analysis

I. van 't Sant [1,2] · M. P. Engbersen [1,2] · P. A. Bhairosing [3] · D. M. J. Lambregts [1] · R. G. H. Beets-Tan [1,2] · W. J. van Driel [4] ·
A. G. J. Aalbers [5] · N. F. M. Kok [5] · M. J. Lahaye [1]

Abstract

Purpose Detection of peritoneal metastases (PM) is key in the staging and management of gastrointestinal and ovarian cancer patients. The purpose of this meta-analysis was to determine the diagnostic performance of CT, PET(CT), and (DW)MRI in detecting PM.
Methods A literature search in Pubmed, Embase (Ovid), and Scopus was performed (January 1997–May 2018) to identify studies reporting on the accuracy of imaging PM in the diagnostic workup of gastrointestinal or ovarian cancers. Inclusion criteria were region-based or patient-based studies comprising > 15 patients, surgery/histology/radiological follow-up as a reference standard, and sufficient data to construct a 2 × 2 contingency table. Two observers performed data extraction. The sensitivity, specificity, and diagnostic odds ratio (DOR) were calculated using a bivariate random-effects model and hierarchical summary operating curves (HSROC) were generated.
Results Of 3457 citations retrieved, twenty-four articles met all inclusion criteria. Thirty-seven datasets could be extracted for analysis including 20 for CT, 10 for PET(CT), and 7 for (DW)MRI. The pooled sensitivity, specificity, and DOR for the detection of PM for region-based studies for CT were 68% (CI, 46–84%), 88%(CI, 81–93%), and 15.9 (CI, 4.4–58.0) respectively; 80% (CI, 57–92%), 90% (CI, 80–96%), and 36.5 (CI, 6.7–199.5) for PET(CT), respectively; 92% (CI, 84–96%), 85% (CI, 78–91%), 63.3 (CI, 31.5–127.3) for (DW)MRI. In the patient-based group, not enough studies were included to make a pooled analysis for (DW)MRI and PET(CT).
Conclusion (DW)MRI and PET(CT) showed comparable diagnostic performance for the detection of peritoneal metastases in ovarian and gastrointestinal cancer patients. Since MRI is more widely available than PET(CT) in clinical practice, this potentially is the imaging method of choice in most centers in the future.
Key Points
• *Detection of peritoneal metastases plays an important role in the accurate staging of cancer patients, however, there is no accepted reference standard for the imaging of peritoneal metastases*
• *This meta-analysis shows that (DW)MRI provided the highest sensitivity for the detection of peritoneal metastases in ovarian and gastrointestinal cancer patients*
• *Although (DW)MRI and PET(CT) show a comparable overall diagnostic performance, (DW)MRI seems to be the imaging method of choice since it is more available in daily practice than PET(CT).*

✉ I. van 't Sant
i.jansen@nki.nl

1   Department of Radiology, The Netherlands Cancer Institute, PO Box 90203, 1006, BE Amsterdam, The Netherlands

2   GROW School of Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands

3   Scientific Information Service, The Netherlands Cancer Institute, Amsterdam, The Netherlands

4   Department of Gynaecology, CGOA location The Netherlands Cancer Institute, PO Box 90203, 1006, BE Amsterdam, The Netherlands

5   Department of Surgery, The Netherlands Cancer Institute, PO Box 90203, 1006, BE Amsterdam, The Netherlands

Abbreviations
CRS   Cytoreductive surgery
DWI   Diffusion-weighted imaging
HIPEC   Hyperthermic intraperitoneal chemotherapy
MRI   Magnetic resonance imaging
PET   Positron emission tomography
PM   Peritoneal metastases

Introduction

Tumor spread to the peritoneum is commonly seen in cancer patients from various origins. For example, approximately 75%, 17%, and 10% of patients with ovarian, gastric, and colorectal cancer, respectively, have peritoneal metastases (PM) at the time of initial presentation [1–3]. PM are an important cause of morbidity and mortality, with only palliative surgery and systemic chemotherapy as conventional treatment options. Median survival rates for PM patients from gastric origin are 1–3 months, for those from colorectal origin this is up to 12.7 months [3, 4]. For ovarian carcinoma, in spite of new treatment modalities, 10-year survival for patients with advanced stage has hardly improved in the last 25 years (10% versus 13%) [5].

Although the presence of PM is certainly considered a poor prognostic sign, it is not proof of distant metastasis [6]. In recent years, aggressive locoregional treatment strategies including cytoreductive (CRS) surgery possibly followed by hyperthermic intraperitoneal chemotherapy (HIPEC) have shown promising results for patients with limited and resectable peritoneal disease [1, 7]. Five-year survival rates as high as 50% in well-selected patient groups of both ovarian and colorectal cancer have been reported [8, 9]. This means that, for a subgroup of patients with PM, prognosis may shift from a palliative treatment to long-term survival or even cure. Accurate staging and selection of patients with a limited peritoneal tumor load is the crux in achieving these optimal results.

Explorative laparoscopy is the reference standard to assess peritoneal disease. However, this procedure is invasive, often challenging and incomplete due to adhesions and carries a small risk of complications. This underlines the need for a robust imaging modality to reliably quantify the extent of peritoneal disease. To date, computerized tomography (CT) still is the preferred imaging method to diagnose PM in most centers. However, there is a growing interest in functional imaging techniques as positron emission tomography (PET) whether or not combined with CT and magnetic resonance imaging (MRI) especially with the addition of diffusion-weighted (DW) sequences.

The purpose of this meta-analysis is to compare the diagnostic performance of CT, PET(CT), and (DW)MRI in the detection of peritoneal metastases in patients with gastrointestinal (i.e., gastric, colorectal, appendiceal) and ovarian cancer in order to indicate the imaging modality most suitable for optimal preoperative selection of potential CRS candidates.

Materials and methods

Literature search

In accordance with the PRISMA guidelines, a systemic literature search was conducted in the databases PubMed, Embase (Ovid), and Scopus to identify relevant articles from January 1997 up to May 2018 [10]. An initial search strategy was set up and carried out in cooperation with an information specialist linked to our hospital (PB).

Search terms used included "peritoneal seeding," "peritoneal metastases," "peritoneal carcinomatosis," "computed tomography," "CT," "FDG-PET," "PET," "PET(CT)," "magnetic resonance imaging," and "MRI" and finally terms as "diagnosis," "staging," "accuracy," combined using "OR" and "AND."

The PRISMA checklist is presented in Appendix 1. The literature search is described in detail in Appendix 2.

Study selection

References retrieved from the database searches were deduplicated and exported to Endnote X7 (Windows) software. First, two abdominal radiologists with respectively 12 and 10 years of clinical experience (M.L., I.vS.) independently screened titles and abstracts. Review articles, meta-analyses, case reports, conference abstracts, animal studies, comments, and letters to the editor were excluded.

Next, if the abstract fulfilled the criteria as stated below or if this was unclear, both readers reviewed the complete original article.

The defined inclusion criteria were:

- Diagnosis of PM in patients with a newly diagnosed primary gastrointestinal (gastric/colorectal/appendix) or ovarian cancer of any histological type and any stage
- CT, PET, PET(CT), and (DW)MRI or a combination of these imaging techniques were used to detect PM.
- Histopathology, surgery, or clinical/radiological follow-up results were used as a reference standard.
- Results were presented in a 2 × 2 contingency table or such a table could be extracted from the article.
- Studies containing 15 or more patients
- Articles were in English

We aimed to only include studies on the detection of PM in newly diagnosed patients, i.e., concerning pretreatment

imaging. Studies comprising merely patients with recurrent disease or patient groups that all underwent previous surgery or neoadjuvant chemotherapy treatment (NACT) were excluded. If surgical history or prior neoadjuvant chemotherapy treatment was not specifically stated in the article, this finding was considered negative.

All histological tumor types were eligible for inclusion. However, because of the known lower detection rate of mucinous carcinomas by 18F-FDG-PET, studies comprising exclusively mucinous primary tumors were excluded in order to be able to compare the results of each imaging modality.

Both region-based and patient-based studies were included. Region-based studies assess peritoneal burden following predefined abdominal regions. In case of a region-based study, averages for all regions together should have been given or should be derivable.

The references of the retrieved articles were subsequently crosschecked for more potentially relevant studies. Inconsistencies between the readers regarding potential eligibility were resolved by consensus.

Data extraction

Data extraction and assessment of methodological quality were undertaken by one of the authors (I.vS.) and checked by a second author (M.L.). Consensus was reached on points of disagreement.

For each study, the following characteristics were extracted using a predesigned form:

Study characteristics Study characteristics are the following: first author, country of origin, year of publication, study design (retro-/prospective), single-/multi-center, primary outcome, reference test (i.e., histopathology, surgical findings, follow up imaging), patient-based or region-based analysis, interval between imaging and reference standard, sample size, prevalence of PM, accuracy, sensitivity, specificity, true-positives/negatives (TP/TN), false-positives/negatives (FP/FN), positive predictive value, and negative predictive value (PPV/NPV).

Patient characteristics Patient characteristics are the following: mean age, gender, primary tumor and histology, and prior NACT.

Imaging characteristics Imaging characteristics are the following: type of imaging modality, basic specifications of imaging modalities and techniques used (i.e., type of scanner, field strength MRI, slice thickness), use of intraluminal and intravenous contrast medium, use of bowel preparation or antispasmolytics. Additionally, specific scoring systems for peritoneal tumor load, e.g., the peritoneal cancer index (PCI) as introduced by Sugarbaker [11], were noted.

If a study did not state TP/TN/FP/FN results, these results were derived from marginal totals or sensitivity and

specificity. If in case of multiple readers mean results were given, these were used for the analyses; if not, results of the first reader were used. If the presence of PM was rated using a grading scale (three or five point with an intermediate "equivocal" grade), results with the threshold where the equivocal category was regarded positive were used.

Corresponding authors were contacted to clarify incomplete or unclear data.

Quality assessment

The methodological quality of all included articles was assessed with the revised tool for the quality assessment of diagnostic accuracy studies (QUADAS-2) [12]. This assessment was performed by one of the authors and checked by another (I.vS., M.L.). Final results were based on consensus discussion.

Statistical analysis

Based on the results derived from 2×2 contingency tables, all diagnostic parameters for the different modalities such as sensitivity, specificity, and diagnostic odds ratio were calculated. The diagnostic odds ratio (DOR) is a measure for the diagnostic performance of a test, which combines sensitivity and specificity into one measure [13]. A DOR of 1 implies that the test has no discriminatory power at all; the larger the DOR, the better the test discriminates between patients with and without the target disorder. Diagnostic performance between articles was summarized and compared with forest plots and hierarchical summary receiver operating characteristic (HSROC) curves with use of a random effects model as described by Moses and Littenberg [14].

Subgroup analyses were performed for studies with different types of tumors to see whether tumor type (GI or ovarian) affected the diagnostic performance of imaging.

The heterogeneity of the study results was evaluated by calculating the I^2 statistic. I^2 values can vary from 0 to 100%. Percentages of around 25% ($I^2 = 25$), 50% ($I^2 = 50$), and 75% ($I^2 = 75$) were classified as low, medium, and high heterogeneity, respectively.

All statistical analyses were performed using StataSE (StataCorp), version 11.

Results

### Literature search and study selection

The initial search in electronic databases resulted in 3457 articles. After deduplication, 2187 articles were excluded by screening the title and/or abstract. The remaining 69 articles were selected for close review of the full article after which

another 50 were excluded for various reasons (Fig. 1). After reference crosscheck of the remaining 19 eligible articles, five additional articles were found that fulfilled all inclusion criteria, adding to a total of 24 included studies. One corresponding author was contacted to clarify unclear data.

Study and patient characteristics of included studies

Characteristics of the included studies are shown in Table 1.

The total number of included patients was 2302 (range 15–498, mean 96). The majority of studies had a retrospective

Fig. 1 PRISMA flow diagram of the search for eligible studies on diagnostic performance of CT, PET(CT), and (DW)MRI for the detection of peritoneal metastases

Table 1 Summary data of 24 included studies

First author	Year	Study	Country	Single(S)/multi-center(M)	Population (M/F)	Primary tumor	Imaging modality	TP	TN	FP	FN
Patient based											
Burbidge, S.	2003	R	UK	S	88 (n.a.)	Gastric	(MD)CT	5	67	1	15
Chen, J.	2005	P	Korea	S	68 (49/19)	Gastric	(spiral) CT	8	52	5	2
							18F-FDG-PET	3	57	1	7
Coakley, F.V.	2002	R	USA	S	64	Ovarian	(spiral) CT	35	21	2	6
Davies, J.	1997	R	UK	S	105 (68/37)	Gastric	(spiral) CT	12	82	6	5
Fujii, F.	2008	R	Japan	S	26	Ovarian	MRI-DW	13	10	1	2
Kawanaka, Y	2016	R	Japan	S	86 (n.a.)	Gastric	CT	30	44	0	12
							PET-CT(dx)	29	44	0	13
Kayaalp, C	2002	P	Turkey	S	107 (n.a.)	Gastric	(spiral)CT	3	83	1	20
Kim, H.W.	2013	R	Korea	M	46	Ovarian	(MD)CT	23	13	7	3
							PET-CT(ld)	25	18	2	1
Kim, J.E.	2012	R	Korea	S	56 (44/12)	Gastric	(MD)CT	18	16	12	10
Kim, S.J.	2009	R	Korea	S	498 (332/166)	Gastric	(MD)CT	27	428	17	26
Lim, J.S.	2006	R	Korea	S	112 (73/39)	Gastric	(spiral/MD)CT	13	87	8	4
							18F-FDG-PET	6	94	1	11
Pan, Z.	2010	P	China	S	350 (220/130)	Gastric	(MD)CT	9	329	11	1
Perlaza, P.	2018	P	Italy	S	50 (30/20)	Gastric	(MD)CT	6	35	0	9
							PET-CT(ld)	6	35	0	9
Qi, Z.	2017	R	China	S	41	Ovarian	(spiral) CT	39	0	0	2
Tempany, C.	2000	P	USA	M	280	Ovarian	(spiral) CT	46	132	30	4
							MRI(+c)	39	107	27	2

First author	Year	Study design	Country	Single (S)/ multi-center (M)	Population (M/F) /nr. of regions	Primary tumor	Imaging modality	TP	TN	FP	FN
Region based											
Choi, H.J.	2011	P	Korea	S	57/741	Ovarian	(MD)CT	114	355	135	137
De Iaco, P.	2011	?	Italy	S	40/346	Ovarian	PET-CT(ld)	243	26	12	65
Hynninen, J.	2013	P	Finland	S	41/720 /693	Ovarian	CT	196	216	20	288
							PET-CT(dx)	237	225	25	226
Klumpp, B.D.	2012	R	Germany	S	15 (4/11)/182	Ovarian+ CRC	PET-CT(dx)	122	49	2	9
							MRI(+c)	114	47	4	17
Low, R.N.	2015	R	USA	S	22 (8/14)/286	Ovarian+ GI	(MD)CT	116	64	10	96
							MRI (DWI+c)	201	52	22	11
Metser, U.	2011	R	Canada	S	76/1845	Ovarian	(MD)CT	337	1351	79	78
Michielsen, K.	2014	P	Belgium	S	32/475	Ovarian	(MD)CT	136	220	47	72
							PET-CT(dx)	108	228	39	100
							MRI (DWI+c)	189	243	24	19
Schmidt, S.	2015	P	Switzerland	S	15/135	Ovarian	(MD)CT	71	56	5	3
							PET-CT(ld)	70	59	2	4
							MRI (DWI+c)	73	51	10	1
Zhang, H.	2018	R	China	S	27 (14/13)/351	CRC	MRI (DWI)	163	125	23	40

P prospective, *R* retrospective, *S* single-center, *M* multi-center, *M/F* male or female (only stated in other than ovarian cancer studies), *CRC* colorectal cancer, *GI* gastrointestinal cancer, *(spiral/MD) CT* spiral and/or multi-detector computed tomography, *18F-FDG-PET* positron emission tomography (not combined with CT), *PET-CT (ld/dx)* positron emission tomography combined with respectively low-dose or diagnostic CT, *MRI DWI/+c* MRI with diffusion-weighted and/or contrast-enhanced sequences, *TP* true positives, *FP* false positives, *TN* true negatives, *FN* false negatives, *n.a.* not available

design (14 out of 24); in one study, the design was not defined [15]. Half of the included studies originated from Asian countries. Two multi-center studies were included [16, 17]. The majority of included studies comprised patients with exclusively ovarian ($n = 11$) or gastric cancer ($n = 10$). Three studies comprised patients with colorectal or appendiceal primaries.

The 24 included articles provided 37 datasets as eleven studies evaluated multiple modalities (Fig. 1). Twenty datasets evaluated the presence of PM with CT [2, 16–34], ten datasets with PET(CT) [15, 17, 19, 21, 25, 27, 30, 33–35], and seven datasets with (DW)MRI [16, 31, 33–37]. Of the CT oriented studies, eleven used multi-detector CT scans, six spiral CT scans, one study used both and two studies did not specify. Of the ten PET(CT) studies, four used low-dose CT, four diagnostic CT (all contrast-enhanced), and two studies used 18F-FDG-PET without accompanying CT scanning. Of the seven MRI studies, in addition to morphological sequences, two studies used contrast-enhanced sequences, two used DWI sequences, and the remaining three studies included both. None of these last-mentioned studies analyzed the accuracy of DWI versus contrast-enhanced sequences separately [31, 33, 34].

Fifteen studies were patient-based whereas nine had a region-based approach. Three of the region-based studies used the peritoneal cancer index (PCI) as a scoring method [31, 35, 37]. Two studies used an adjusted PCI score comprising nine instead of 13 abdominal regions (implants on small bowel serosa not assessed) [15, 34].

The majority of patient-based studies (10 out of 15) comprised gastric cancer patients whereas the majority of region-based studies comprised ovarian cancer patients exclusively or as part of mixed cohort (respectively 6 and 2 out of 9 studies). Of the patient-based studies, 67% (10 out of 15) was published in or before 2010 whereas all of the region-based studies were published after 2010 (2011–2018).

Three included studies used follow-up imaging as part of the reference standard [21, 27, 32]. In one study, postoperative CT and clinical data were used as a reference standard only for lesions identified on preoperative CT but not found at surgery [32]. The other two studies used follow-up imaging for patients that did not undergo surgery [21, 27]. Method of follow-up imaging is not clearly stated in these studies.

Quality assessment

The results of the QUADAS-2 assessments are presented in Fig. 2a, b.

In the reference standard domain 58% (14 of 24 studies) scores "unclear." In most of these studies, it was unknown whether the reference standard results were truly blinded to index test results, thus introducing potential bias [2, 17, 18, 21, 22, 24, 26–28, 33, 34, 36, 38, 39]. In a quarter of the included

studies, there was a high risk of bias in the patient selection domain. This was mainly caused by inappropriate exclusions.

Seven studies provided insufficient information on timing between index test and reference standard. The remaining studies had an acceptable time frame between imaging and reference standard (range from days to 59 days) [18, 19, 21, 22, 25–27, 37].

Regarding applicability concerns for patient selection, index test and reference standard were generally low. None of the studies was deemed necessary to exclude from the meta-analysis based on QUADAS-2 assessment.

Meta-analysis

Pooled analysis of sensitivity, specificity, and diagnostic odds ratio of CT, PET(CT), and (DW)MRI

Comparison between CT, PET(CT), and (DW)MRI in the region-based group shows (DW)MRI to have the highest sensitivity (91%; CI, 84–96%) and diagnostic odds ratio (63.3, CI, 31.5–127.3) (Table 2). PET(CT) has the highest specificity (90%; CI, 80–96%) however with only a marginal difference from (DW)MRI and CT (respectively 85% (CI, 78–91%) and 88% (CI, 81–93%)). Figure 3 shows the hierarchical summary receiver operating characteristics (HSROC) curves of region-based CT, PET(CT), and (DW)MRI studies.

In the patient-based group, not enough studies were included to make a pooled analysis for (DW)MRI and PET(CT). Pooled analysis of patient-based CT studies ($n = 14$) showed a higher DOR than for the region based ones ($n = 6$): DOR 33.5 (16.3–68.9) versus 15.9 (4.4–58.0). However, sensitivity and specificity showed only small differences (Table 2).

The test for heterogeneity showed there was considerable heterogeneity among studies for all modalities ($I^2 > 75\%$). Forest plots of all studies, with their pooled estimates per modality and the I^2 score per modality, are presented in Fig. 4.

Sub-analyses

There were not enough data available to compare PET with low-dose CT versus PET with diagnostic CT scans or MRI with versus MRI without DW sequences in both patient- or region-based groups.

There was no significant difference in sensitivity and specificity between prospective and retrospective CT patient-based studies with sensitivity and specificity respectively of 71% (CI, 30–94%) and 95% (CI, 84–99%) versus 68% (CI, 54–81%) and 93% (CI, 82–97%).

Comparing type of CT scanner (spiral/multi-detector) and year of publication ($\leq 2010/> 2010$) did not show significant differences (Appendix 3). There was not enough data available to compare primary tumors (ovarian/gastric) and slice thickness ($</> 5$ mm).

a

Study	RISK OF BIAS				APPLICABILITY CONCERNS		
	PATIENT SELECTION	INDEX TEST	REFERENCE STANDARD	FLOW AND TIMING	PATIENT SELECTION	INDEX TEST	REFERENCE STANDARD
Burbidge et al.	☹	☺	?	☺	☺	☺	☺
Chen et al.	☺	☺	☺	?	☺	☺	☺
Choi et al.	☺	☺	?	☺	☺	☺	☺
Coakley et al.	☺	☺	?	☺	☺	☹	☺
Davies et al.	☺	☺	☺	☺	☺	☺	☺
De Iaco et al.	☺	☺	☺	☺	☺	☺	☺
Fuji et al.	☺	☺	?	☺	☺	☺	☺
Hynninen et al.	☺	☺	☹	☺	☺	☺	☺
Kawanaka et al.	?	☺	?	?	☹	☺	☺
Kayaalp et al.	☺	☺	?	?	☹	☹	☺
Kim H.W. et al.	☺	☺	?	☺	☺	☺	☺
Kim J.E. et al.	☹	☺	☹	☺	☹	☺	☺
Kim S.J. et al.	☺	☺	?	☺	☺	☺	☺
Klumpp et al.	☹	☺	?	☺	☹	☺	☺
Lim et al.	☹	☺	☺	?	☺	☺	☹
Low et al.	☹	☺	☺	☺	☺	☺	☺
Metser et al.	☺	☺	☺	☺	☺	☺	☺
Michielsen et al.	☺	☺	?	☺	☺	☺	☺
Pan et al.	☺	☺	?	?	☺	☺	?
Perlaza et al.	☺	☺	?	?	☺	☺	☺
Qi et al.	☹	☺	?	☺	☺	☺	☺
Schmidt et al.	☺	☺	?	☺	☺	☺	☺
Tempany et al.	☺	☺	☹	☺	☺	☺	☺
Zhang et al.	?	☺	☺	?	☺	☺	☺

☺ = low risk, ☹ = high risk, ? = unclear risk

b

Fig. 2 **a** QUADAS-2 results. Risk of bias and applicability concerns per study. **b** QUADAS-2 results. Overview of risk of bias and applicability concerns of all 24 included studies

Discussion

This meta-analysis showed that (DW)MRI provided the highest sensitivity for the detection of peritoneal metastases in patients with tumors from gastrointestinal or ovarian origin. PET(CT) shows a lower, albeit not significant, diagnostic performance than (DW)MRI: pooled sensitivity, specificity, and DOR for PET(CT) 80% (CI, 57–92%); 90%(CI, 80–96%); 36.5 (CI, 6.7–199.5) and for (DW)MRI 92%(CI, 84–96%); 85%(CI,78–91%); 63.3 (CI, 31.5–127.3), respectively.

Table 2 Summary of statistics on diagnostic performance of CT, PET(CT), and (DW)MRI in detecting peritoneal metastases (region based studies)

Modality	Sensitivity	Specificity	Diagnostic OR
Region based			
CT	0.68 (0.46–0.84)	0.88 (0.81–0.93)	15.9 (4.38–58.01)
PET(CT)	0.79 (0.092)	0.90 (0.80–0.96)	36.5 (6.7–200.0)
(DW)MRI	0.91 (0.96)	0.85 (0.78–0.91)	63.3 (31.5–127.3)
Patient based			
CT	0.70 (0.53–0.83)	0.94 (0.87–0.97)	33.5 (16.3–69.0)

Data in parentheses are 95% confidence interval, *OR* odds ratio

However, (DW)MRI is more easily available in daily practice than PET(CT) and is therefore potentially the imaging method

of choice. CT demonstrated the lowest sensitivity rate compared with (DW)MRI and PET(CT) (68% (CI, 46–84%)).

As radiological manifestations of PM are variable and can be subtle, interpretation may be challenging. At present, there is no accepted reference standard for imaging peritoneal metastases. In this meta-analysis CT by far comprised the largest dataset, reflecting the fact that in most centers, this is currently the preoperative imaging method of choice for diagnosing PM. This is probably due to its availability, speed of acquisition, and familiarity. In the literature, the reported sensitivity of CT in diagnosing PM ranges widely from 25 to 90% [2, 40]. Detection of peritoneal implants on CT is strongly influenced by lesion size, location and presence of ascites [41]. Studies report a sensitivity of detection of individual peritoneal implants < 1.0 cm ranging from only 9.1–50% and of

Fig. 3 Hierarchical summary receiver operating curves (HSROC) for the diagnostic performance of (**a**) CT, (**b**) PET(CT), and (**c**) (DW)MRI for determining the presence of peritoneal metastases on a per region basis. Each circle on the plot represents the pair of sensitivity and specificity from a study and the size of the circle is scaled according to the sample size of the study. The solid red block represents the summary sensitivity and specificity, and this summary point is surrounded by a 95% confidence region (orange dashed line) and 95% prediction region (green dotted line). HSROC curve is plotted as curvilinear line passing through summary point. indicates (DW)MRI to have the highest summary point and the highest confidence level indicating that from current literature (DW)MRI seems most adequate to detect peritoneal malignancies at region-based analysis

Fig. 4 Forest plots of all studies and their pooled estimates per modality. **a** CT per region analysis. **b** PET(CT) per region analysis. **c** (DW)MRI per region analysis. **d** CT per patient analysis. Each horizontal line represents an individual study with the result plotted as a box and the 95% confidence interval displayed as the line. The diamond at the bottom of each plot shows the result of the individual studies combined and averaged. The horizontal lines of the diamond are the limits of the 95% confidence intervals. From the forest plots, the specificities of all three modalities seem to perform similarly however the sensitivity of (DW)MRI is higher than that of CT and PET(CT) and PET-CT at region-based detection of peritoneal metastases. For each modality, the degree of heterogeneity between the studies is indicated by the I^2 statistic in the left bottom corner

nodules < 0.5 cm only 11% [40, 42]. This is mainly caused by its limited contrast resolution, making especially small nodules hardly discernible from adjacent normal tissue. As a result, CT consistently and significantly underestimates the peritoneal tumor load. Substantial understaging of PM is undesirable, as it erroneously labels patients as operable, which might lead to futile surgery.

Functional imaging techniques like PET-CT and DW MRI seem to overcome some of the limitations of CT. Both techniques show a high contrast between tumor and normal surrounding tumor (signal to noise ratio). In addition to detailed anatomical data, PET-CT reflects increased glucose metabolism in tumors whereas DW MRI reflects tumoral cellularity. The most important advantage of PET(CT) is the fact that it is a total body imaging technique that can possibly detect distant metastases elsewhere. Its major drawbacks are its radiation

exposure, higher cost, and limited depiction of small tumor volumes (current spatial resolution 4 mm). MRI is radiation free and with a dedicated protocol, it might detect smaller peritoneal lesions potentially missed by PET-CT. Potential drawbacks of DW MRI are false-positive findings caused by, for instance, postoperative abnormalities or lymph nodes.

A recent meta-analysis on the diagnostic accuracy of 18F-FDG PET/CT for the detection of peritoneal carcinomatosis of various cancers found a sensitivity and specificity of respectively 87% (CI 0.77–0.93) and 92% (CI 0.89–0.94) [43]. In the first prospective study evaluating the diagnostic value of whole-body DW MRI compared with CT and PET-CT in assessing peritoneal staging in ovarian cancer patients, Michielsen et al reported accuracies of 91%, 75%, and 71%, respectively. In particular mesenteric and serosal deposits and subcentimetric lesions were better described by DW MRI than

by CT [33]. It must be emphasized that this study used a dedicated MRI protocol that, besides DWI and post-contrast series, included proper bowel preparation combining antispasmodics with negative oral contrast fluid to suppress signal from bowel content. Combined gadolinium-enhanced and DWI images in addition to morphological sequences has to highest accuracy compared with either sequence alone [33, 44, 45]. In our experience too, these sequences further complement each in many instances, hereby reducing false readings. Unfortunately, the number of MRI studies in this meta-analysis was insufficient to perform a sub-analysis between studies using both DWI and post-gadolinium series versus those using only post-gadolinium series in addition to morphological sequences.

Despite the suboptimal performance of CT, a previous meta-analysis on the diagnostic performance of CT and (DW)MRI for detecting peritoneal metastases still concluded that CT should be the preferred imaging modality for detecting peritoneal metastases [46]. This conclusion, however, was mainly drawn based on the robustness of data as the number of included MRI studies at that time was much smaller than the number of included CT studies (3 versus 19). More recent literature demonstrates that MRI with DW sequences significantly outperforms CT for estimation of spread of PM, overall staging and prediction of operability in colorectal cancer patients [47, 48].

Major strength of this study is that it is the first meta-analysis that could include enough MR studies to compare all currently available imaging techniques used to assess peritoneal disease. However, there are also several limitations. Although heterogeneity of included patient groups was fairly limited (primary staging, only gastrointestinal, and ovarian tumors), there remained considerable heterogeneity in study design and imaging variables (e.g., scanners, protocols, sequences, intravenous/oral contrast, readers' profession and experience). Second, in more than half of the included studies, it was unknown whether the reference standard results were blinded to index test results. An explanation for this might be that most articles were published in radiological journals where there is less emphasis on surgical and histopathological aspects. In another three studies, reference standard results were reported not to be blinded to index test results. Moreover, reference standard ranged from histopathological analysis to surgical findings to radiological follow-up. This may have introduced interpretation bias. Third, although the original search terms of this study included ovarian and gastrointestinal primaries, the vast majority of the included non-ovarian studies consisted of cohorts with merely gastric cancer patients. In just three studies, patients with colorectal or appendix tumors were included. Lastly, since PET imaging is uncommon in patients with mucinous primary tumors because of its very low sensitivity in the detection of these tumors, studies comprising exclusively mucinous tumors were excluded from this meta-analysis. In our opinion, including this patient population would have led to a bias because the results of CT, MRI, and PET imaging would be compared while different populations were studied for each modality.

In summary, the detection of peritoneal metastases plays an important role in the accurate staging of cancer patients, helping to optimally guide patient management. With all currently available and promising surgical and oncological treatment options, there is an increasing demand for preoperative detection of peritoneal disease in order to tailor the right treatment for an individual patient. This meta-analysis suggests that (DW)MRI is the preferred imaging method to assess peritoneal tumor load. In the future, DW MRI is expected to be increasingly implemented alongside and above CT and PET-CT as a standard workup tool for imaging peritoneal metastases.

Compliance with ethical standards

Guarantor The scientific guarantor of this publication is M. Lahaye.

Conflict of interest The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.

Statistics and biometry One of the authors has significant statistical expertise.

Informed consent Written informed consent was not required for this study because the article type is a meta-analysis.

Ethical approval Institutional Review Board approval was not required because the article type is a meta-analysis.

Methodology
•meta-analysis
•performed at one institution

References

1. Kok NF, de Hingh IH (2017) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastases of colorectal origin. Br J Surg 104:313–315
2. Coakley FV, Choi PH, Gougoutas CA et al (2002) Peritoneal metastases: detection with spiral CT in patients with ovarian cancer. Radiology 223:495–499
3. Spiliotis J, Halkia E, de Bree E (2016) Treatment of peritoneal surface malignancies with hyperthermic intraperitoneal chemotherapy-current perspectives. Curr Oncol 23:e266–e275
4. Segelman J, Granath F, Holm T, Machado M, Mahteme H, Martling A (2012) Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg 99:699–705
5. Timmermans M, Sonke GS, Van de Vijver KK, van der Aa MA, Kruitwagen R (2018) No improvement in long-term survival for

epithelial ovarian cancer patients: a population-based study between 1989 and 2014 in the Netherlands. Eur J Cancer 88:31–37

6. Witkamp AJ, de Bree E, Van Goethem R, Zoetmulder FA (2001) Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy. Cancer Treat Rev 27:365–374

7. van Driel WJ, Koole SN, Sikorska K et al (2018) Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 378:230–240

8. Huo YR, Richards A, Liauw W, Morris DL (2015) Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: a systematic review and meta-analysis. Eur J Surg Oncol 41:1578–1589

9. Elias D, Mariani A, Cloutier AS et al (2014) Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin. Eur J Surg Oncol 40:1467–1473

10. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097

11. Sugarbaker PH (2010) Surgical responsibilities in the management of peritoneal carcinomatosis. J Surg Oncol 101:713–724

12. Whiting PF, Rutjes AW, Westwood ME et al (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155:529–536

13. Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM (2003) The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol 56:1129–1135

14. Moses LE, Shapiro D, Littenberg B (1993) Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med 12:1293–1316

15. De Iaco P, Musto A, Orazi L et al (2011) FDG-PET/CT in advanced ovarian cancer staging: value and pitfalls in detecting lesions in different abdominal and pelvic quadrants compared with laparoscopy. Eur J Radiol 80:e98–e103

16. Tempany CM, Zou KH, Silverman SG, Brown DL, Kurtz AB, McNeil BJ (2000) Staging of advanced ovarian cancer: comparison of imaging modalities–report from the Radiological Diagnostic Oncology Group. Radiology 215:761–767

17. Kim HW, Won KS, Zeon SK, Ahn BC, Gayed IW (2013) Peritoneal carcinomatosis in patients with ovarian cancer: enhanced CT versus 18F-FDG PET/CT. Clin Nucl Med 38:93–97

18. Burbidge S, Mahady K, Naik K (2013) The role of CT and staging laparoscopy in the staging of gastric cancer. Clin Radiol 68:251–255

19. Chen J, Cheong JH, Yun MJ et al (2005) Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography. Cancer 103:2383–2390

20. Davies J, Chalmers AG, Sue-Ling HM et al (1997) Spiral computed tomography and operative staging of gastric carcinoma: a comparison with histopathological staging. Gut 41:314–319

21. Kawanaka Y, Kitajima K, Fukushima K et al (2016) Added value of pretreatment ^{18}F-FDG PET/CT for staging of advanced gastric cancer: comparison with contrast-enhanced MDCT. Eur J Radiol 85:989–995

22. Kayaalp C, Arda K, Orug T, Ozcay N (2002) Value of computed tomography in addition to ultrasound for preoperative staging of gastric cancer. Eur J Surg Oncol 28:540–543

23. Kim JE, Lee MW, Moon JW et al (2012) CT detection of dry peritoneal seeding in patients with advanced gastric cancer. Hepatogastroenterology 59:2202–2206

24. Kim SJ, Kim HH, Kim YH et al (2009) Peritoneal metastasis: detection with 16- or 64-detector row CT in patients undergoing surgery for gastric cancer. Radiology 253:407–415

25. Lim JS, Kim MJ, Yun MJ et al (2006) Comparison of CT and 18F-FDG pet for detecting peritoneal metastasis on the preoperative evaluation for gastric carcinoma. Korean J Radiol 7:249–256

26. Pan Z, Zhang H, Yan C et al (2010) Determining gastric cancer resectability by dynamic MDCT. Eur Radiol 20:613–620

27. Perlaza P, Ortin J, Pages M et al (2018) Should 18F-FDG PET/CT Be Routinely performed in the clinical staging of locally advanced gastric adenocarcinoma? Clin Nucl Med 43:402–410

28. Qi Z, Zhang Y, Dai Q, Xia Y, Jiang Y (2017) Peritoneal carcinomatosis in primary ovarian cancer: ultrasound detection and comparison with computed tomography. Ultrasound Med Biol 43:1811–1819

29. Choi HJ, Lim MC, Bae J et al (2011) Region-based diagnostic performance of multidetector CT for detecting peritoneal seeding in ovarian cancer patients. Arch Gynecol Obstet 283:353–360

30. Hynninen J, Kemppainen J, Lavonius M et al (2013) A prospective comparison of integrated FDG-PET/contrast-enhanced CT and contrast-enhanced CT for pretreatment imaging of advanced epithelial ovarian cancer. Gynecol Oncol 131:389–394

31. Low RN, Barone RM, Lucero J (2015) Comparison of MRI and CT for predicting the Peritoneal Cancer Index (PCI) preoperatively in patients being considered for cytoreductive surgical procedures. Ann Surg Oncol 22:1708–1715

32. Metser U, Jones C, Jacks LM, Bernardini MQ, Ferguson S (2011) Identification and quantification of peritoneal metastases in patients with ovarian cancer with multidetector computed tomography: correlation with surgery and surgical outcome. Int J Gynecol Cancer 21:1391–1398

33. Michielsen K, Vergote I, Op De Beeck K et al (2014) Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT. Eur Radiol 24:889–901

34. Schmidt S, Meuli RA, Achtari C, Prior JO (2015) Peritoneal carcinomatosis in primary ovarian cancer staging: comparison between MDCT, MRI, and 18F-FDG PET/CT. Clin Nucl Med 40:371–377

35. Klumpp BD, Schwenzer N, Aschoff P et al (2013) Preoperative assessment of peritoneal carcinomatosis: intraindividual comparison of 18F-FDG PET/CT and MRI. Abdom Imaging 38:64–71

36. Fujii S, Matsusue E, Kanasaki Y et al (2008) Detection of peritoneal dissemination in gynecological malignancy: evaluation by diffusion-weighted MR imaging. Eur Radiol 18:18–23

37. Zhang H, Dai W, Fu C et al (2018) Diagnostic value of whole-body MRI with diffusion-weighted sequence for detection of peritoneal metastases in colorectal malignancy. Cancer Biol Med 15:165–170

38. Choi EK, Yoo Ie R, Park HL et al (2012) Value of surveillance (18)F-FDG PET/CT in colorectal cancer: comparison with conventional imaging studies. Nucl Med Mol Imaging 46:189–195

39. Klumpp BD, Aschoff P, Schwenzer N et al (2012) Peritoneal carcinomatosis: comparison of dynamic contrast-enhanced magnetic resonance imaging with surgical and histopathologic findings. Abdom Imaging 37:834–842

40. de Bree E, Koops W, Kroger R, van Ruth S, Witkamp AJ, Zoetmulder FA (2004) Peritoneal carcinomatosis from colorectal or appendiceal origin: correlation of preoperative CT with intraoperative findings and evaluation of interobserver agreement. J Surg Oncol 86:64–73

41. Dirisamer A, Schima W, Heinisch M et al (2009) Detection of histologically proven peritoneal carcinomatosis with fused 18F-FDG-PET/MDCT. Eur J Radiol 69:536–541

42. Koh JL, Yan TD, Glenn D, Morris DL (2009) Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. Ann Surg Oncol 16:327–333

43. Kim SJ, Lee SW (2018) Diagnostic accuracy of (18)F-FDG PET/CT for detection of peritoneal carcinomatosis; a systematic review and meta-analysis. Br J Radiol 91:20170519

44. Low RN, Sebrechts CP, Barone RM, Muller W (2009) Diffusion-weighted MRI of peritoneal tumors: comparison with conventional MRI and surgical and histopathologic findings–a feasibility study. AJR Am J Roentgenol 193:461–470

45. Espada M, Garcia-Flores JR, Jimenez M et al (2013) Diffusion-weighted magnetic resonance imaging evaluation of intra-abdominal sites of implants to predict likelihood of suboptimal cytoreductive surgery in patients with ovarian carcinoma. Eur Radiol 23:2636–2642

46. Laghi A, Bellini D, Rengo M et al (2017) Diagnostic performance of computed tomography and magnetic resonance imaging for detecting peritoneal metastases: systematic review and meta-analysis. Radiol Med 122:1–15

47. van 't Sant I, van Eden WJ, Engbersen MP et al (2018) Diffusion-weighted MRI assessment of the peritoneal cancer index before cytoreductive surgery. Br J Surg. https://doi.org/10.1002/bjs.10989

48. Dresen RC, De Vuysere S, De Keyzer F et al (2019) Whole-body diffusion-weighted MRI for operability assessment in patients with colorectal cancer and peritoneal metastases. Cancer Imaging 19:1